AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02878460 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: monitoring with SpO2
Description: If SpO2 is below the upper individualized limit, the FiO2 (or oxygen flow) is not changed.~If SpO2 is equal or above this limit, Nurses must reduce the FiO2 (or oxygen flow) by 10% every 10 minutes until SpO2 is ≤ upper individualized limit, with FiO2≥25 %.~if SpO2 is \< lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called.
Study NCT02453477 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene
Description: Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously.
Study NCT01156402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Families-Childhood Obesity Prevention and Oral Health
Description: The active intervention was adapted from the We Can! parent intervention to be culturally-appropriate for Hispanic families of children ages 5-7. The tailored intervention is based on Social Cognitive Theory and Behavioral Choice Theory to provide parents and children with cognitive and behavioral skills to enable change in the target behaviors, and to encourage them to practice using these skills to strengthen their perceived competence in using these behaviors effectively.
Study NCT04967586 — intervention group
Intervention type: OTHER
Intervention: No intervention, questioner only
Description: questioner only
Study NCT03298256 — intervention group
Intervention type: RADIATION
Intervention: EOS X-rays
Description: Full length, orthogonal anteroposterior and lateral X-rays will be taken simultaneously in a standardised standing position, with arms folded anteriorly in 45 degrees . All radiographs will include C7 proximally and the femoral heads distally. 3D reconstruction of the spine can be performed. X-rays will be repeated after the brace is applied, and at intervals of no fewer than 6 months until the brace is weaned off, or if surgical intervention is required. Coronal, sagittal and axial parameters will be calculated from the reconstruction. 3D vertebral wedging will be calculated in the posterofrontal, sagittal and diagonal planes at the apex, 3 superior and 3 inferior vertebrae, as described by Scherrer et al. Changes in the pre- and post-bracing and follow-up parameters can be calculated.
Study NCT01917357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quinvaxem in Uniject
Study NCT02001077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Study NCT02001077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Pain (CBT-P)
Study NCT01917357 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quinvaxem in single dose vials
Study NCT03788668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyoid suspension
Description: Hyoid suspension will be done with barbed reposition pharyngoplasty
Study NCT00902980 — intervention group
Intervention type: OTHER
Intervention: Chart Review
Description: Chart review of patients / graft outcome in renal transplant recipients
Study NCT02134613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 99mTc-anti-TNF-alpha Scintigraphy
Description: 99mTc-anti-TNF-alpha Scintigraphy will be analysed and discussed by physicians who are in charge of the patients.
Study NCT01233414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: The Parent Training program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute treatment sessions over a 24-week period. Topics covered in the program include reinforcement, teaching compliance, and functional communication. The treatment sessions employ direct instruction, review of video-taped examples, practice activities, behavior rehearsal with feedback, and role-playing to accomplish specific skill acquisition. Parents will be given specific homework assignments between sessions.
Study NCT01233414 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Program
Description: The Psychoeducational program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute informational sessions over a 24-week period. The program provides an overview on a variety of topics including the complexities of a PDD diagnosis, co-occurring medical conditions, relevant aspects of child development, use of medications, treatment options for challenging behavior, nutritional issues, and complementary and alternative treatments.
Study NCT01619462 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Prevenar 13 and Synflorix
Description: 260 children will be randomized to receive either Prevenar 13 or Synflorix at 1-2-3 months. At 9 months 65 children in the Prevenar 13 arm and 65 children in the Synflorix arm will receive booster dose of Pneumovax and at 23 months all children will receive a micro dose of Pneumovax.Blood will be collected at 1, 4, 9, 10, 23 and 24 months to determine serotype-specific antibody responses. Nasopharyngeal swabs will also be collected to measure carriage of pneumococci and non-typeable Haemophilus influenzae.
Study NCT02906696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Given PO
Study NCT02906696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03410810 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI analysis
Study NCT03410810 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neurodevelopmental/Neuropsychological Assessment
Description: Standardized Cognitive and Developmental Tests
Study NCT00986986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release niacin
Description: Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.
Study NCT02160028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anesthetics and extended information before dental treatment
Description: The extended information is a comprehensive explanation about what to expect of the treatment and the anesthetic method, phrased in positive words and opening up for questions after information is given.
Study NCT02160028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: anesthetics and standard information before dental treatment
Description: The standard information is short and concise, telling in neutral words what to expect.
Study NCT02736591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI.
Study NCT02736591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone-Releasing Hormone
Description: Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
Study NCT02736591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 1
Description: Women will receive an oral placebo similar to DHEA for 12 weeks before ICSI.
Study NCT02736591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Women will receive a placebo injection similar to growth hormone daily from day 6 of hMG stimulation until the day of hCG triggering.
Study NCT03233204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT00412594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT00412594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00412594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04272606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Antifibrinolytic Agent
Study NCT04272606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Placebo
Study NCT04272606 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Visual Acuity Exam
Description: Supplemented into standard of care daily neurological exam on day of surgery and day after
Study NCT04272606 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual Acuity Exam
Description: Supplemented into standard of care daily neurological exam on day of surgery and day after
Study NCT04272606 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: 3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)
Description: 3D-CAM is a brief verbal assessment tool that can be used to test patients and study patients for delirium.
Study NCT04272606 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)
Description: 3D-CAM is a brief verbal assessment tool that can be used to test patients and study patients for delirium.
Study NCT02795845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum
Description: Probiotic
Study NCT02795845 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule without active ingredient
Study NCT01813513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: 50 mg tablet for oral administration
Study NCT04012658 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02879799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implement Family Integrated Care
Description: Specially trained FICare nurses will provide education and support for families to provide care for the baby while they are present in the NICU. Study mothers will meet with veteran parents for additional support. Families will keep a log of their activities and costs.
Study NCT02949076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Unilateral lower limb resistance exercise will be performed 3 times per week for 8 weeks in non-small cell lung cancer patients on only one leg, while the contralateral leg serves as a non-exercising control.
Study NCT01813513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: 150 mg capsule for oral administration
Study NCT02817698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabis
Description: All cannabis dependent subjects will use cannabis cigarettes to induce elevated dopamine and beta endorphin levels in the brain.
Study NCT00550862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT-747
Description: Once a day (QD) by mouth (PO)
Study NCT04515628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Specified dose on specified days
Study NCT00550862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: INT-747
Description: Once a day (QD) by mouth (PO)
Study NCT00550862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid (URSO)
Description: Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.
Study NCT00550862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ursodeoxycholic Acid (URSO)
Description: Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.
Study NCT00550862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04237558 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal hysterectomy
Description: Vaginal hysterectomy by removal of uterus through vagina in absence of prolapse
Study NCT04237558 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic hysterectomy
Description: Laparoscopic hysterectomy through key hole surgery through small incisions of the abdomen
Study NCT03150394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GASTRUS
Description: Gastrus will be given from the first day of eradication treatment to completion after 30 days of treatment
Study NCT03150394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo will be given from the first day of eradication treatment to completion after 30 days of treatment
Study NCT02036671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access
Study NCT03380104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradural Spinal Cord Stimulation
Description: The device will be placed percutaneously at the lumbar spine at L2-3 or L3-4 level into the intrathecal CSF space and advanced to the T8-10 disc space. After positioning of the intrathecal lead, the stimulation catheter will be run through a standardized experimental algorithm consisting on various frequencies.
Study NCT03380104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Administration of Questionnaires
Description: Subjects will be administered questionnaires to evaluate pain, quality of life, and global function prior the study, at 1 hour after the completion of the study, and at 4 day follow-up appointment.
Study NCT01704001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART-123
Description: 380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days
Study NCT03662113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: 5ml Domperidone prior to VCE
Study NCT03662113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: water
Description: 5ml water prior to VCE
Study NCT03039491 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine 23 valent
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae
Study NCT03039491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine 23 valent
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae
Study NCT04515628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branebrutinib
Description: Specified dose on specified days
Study NCT05993520 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: Between June 2020 and June 2023, 36 volunteer participants aged 18 and above, who were receiving treatment in the Department of Chest Diseases at Istanbul University, Istanbul Faculty of Medicine, and met the inclusion criteria, were included in the project. Participants' respiratory function tests, respiratory muscle functions, dyspnea levels, cough, sleep quality, peripheral muscle strength, quality of life, exercise capacity, and fatigue levels were evaluated.
Study NCT00239681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral
Study NCT00239681 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT01653249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®
Study NCT00688077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitonin
Description: Calcitonin 200 IU/ml, single subcutaneous injection, experimental group
Study NCT00688077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
Study NCT01293799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up of PD patients´ theoretical and practical skills
Description: Testing of patients knowledge and retraining if needed
Study NCT00103272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT00103272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT02230306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60mg once a day; will be taken on days 1-21 of each 28 day treatment cycle; will be taken in combination with Vemurafenib;
Study NCT02230306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960mg twice a day; 28 day treatment cycle; will be taken in combination with Cobimetinib;
Study NCT02447276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475
Study NCT02447276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02790112 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GnRHas
Description: Influence of early adiposity rebound, genetic polymorphisms and GnRHa treatment on long-term outcome of treated and untreated girls with idiopathic central precocious compared to a control group.~puberty.
Study NCT04848376 — intervention group
Intervention type: DEVICE
Intervention: (1) SmartLoc (2) SmartLoc Evo (3) Winloc(4) Vigor PEEK Cervical Disc Spacer (5) Combo C (6) Polymer Lumbar Disc Spacer (7) X'Plo (8) Rainboo (9) Combo L
Description: As long as there are patients using the above device, conduct questionnaire interview.
Study NCT03975296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoperative single-shot TMQLB
Description: The patient is placed in the lateral position. The curved probe of Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
Study NCT03975296 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative single-shot TPVB
Description: The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The curve probe of ultrasound scanner is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine is injected into the paravertebral space of T10.
Study NCT03975296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patient controlled intravenous analgesia(PCIA)
Description: at the end of surgery, patient is administered a PCIA with morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
Study NCT03975296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patient controlled intravenous analgesia(PCIA)
Description: at the end of surgery, patient is administered a PCIA with morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
Study NCT01800539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Education Model (PEM)
Description: Providers will be trained to use evidence-based practices for early intervention service delivery in the Autism Spectrum Disorder population.
Study NCT01913626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive group therapy
Description: the cognitive group therapy is composed of eight meetings including information about memory processes, learning and practicing tools and strategies to improve cognition and memory.
Study NCT03638258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Cream 0.3%
Description: Applied once daily for 12 weeks
Study NCT03638258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Cream 0.15%
Description: Applied once daily for 12 weeks
Study NCT03638258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Applied once daily for 12 weeks
Study NCT06647199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the plaque index (PI)
Description: Peri-implant soft tissue changes as regards plaque was assessed employing the modiﬁed plaque index (PI). Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD).